Hexima Ltd (AU:HXL)
ASX:HXL
Want to see AU:HXL full AI Analyst Report?
HXL Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.01
Previous CloseN/A
Volume15.80K
Average Volume (3M)0.00
Market Cap
AU$2.17M
Enterprise Value-AU$992.93K
Total Cash (Recent Filing)AU$1.54M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding41,759,846
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)AU$47.10M
Bulls Say, Bears Say
Bulls Say
Platform R&D FocusHexima’s peptide-based antifungal and antimicrobial R&D, centered on plant defensins, represents a platform strategy addressing structural infectious-disease needs. Platform-driven pipelines create durable optionality across programs and sustain long-term value if clinical progress continues.
Low LeverageEffectively zero debt reduces refinancing and interest-rate risk and preserves strategic optionality for a small biotech. Low leverage gives management time to advance clinical programs without near-term debt pressure, a durable structural advantage during lengthy development cycles.
Reduced Cash Burn Trend2025 shows smaller operating and free cash outflows versus prior years, indicating improving cash efficiency and cost discipline. A sustained reduction in burn extends runway, increasing the chance management can reach value-driving milestones before requiring further funding.
Bears Say
Persistent LossesThe firm remains consistently loss-making with virtually no revenue in recent years, signaling weak commercialization momentum. Over the medium term, absence of recurring revenue means continued reliance on R&D outcomes or external deals to create sustainable cash flows, a high-risk dependency.
Ongoing Cash BurnNegative operating and free cash flow across all reported years creates persistent cash burn. This structural deficit forces reliance on external funding or partnerships, increasing dilution risk and constraining the company's ability to self-fund multiple programs or commercial initiatives.
Eroding Equity BaseEquity declining from ~4.6M to ~1.5M over three years reflects accumulated losses and a thinning capital buffer. A smaller equity base increases the probability of capital raises, heightens dilution risk, and reduces financial flexibility to absorb clinical setbacks or pursue parallel development paths.
Hexima Ltd News
HXL FAQ
What was Hexima Ltd’s price range in the past 12 months?
Hexima Ltd lowest share price was AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Hexima Ltd’s market cap?
Hexima Ltd’s market cap is AU$2.17M.
When is Hexima Ltd’s upcoming earnings report date?
Hexima Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 117 days.
How were Hexima Ltd’s earnings last quarter?
Hexima Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.
Is Hexima Ltd overvalued?
According to Wall Street analysts Hexima Ltd’s price is currently Overvalued.
Does Hexima Ltd pay dividends?
Hexima Ltd does not currently pay dividends.
What is Hexima Ltd’s EPS estimate?
Hexima Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hexima Ltd have?
Hexima Ltd has 41,759,846 shares outstanding.
What happened to Hexima Ltd’s price movement after its last earnings report?
Hexima Ltd reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hexima Ltd?
Currently, no hedge funds are holding shares in AU:HXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hexima Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-32.19%
Trailing 12-Months
Asset Growth
-14.34%
Trailing 12-Months
Company Description
Hexima Ltd
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.
Technical Analysis
Vectus Biosystems Limited
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―